HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Sumatriptan (Imigran)

Subscribe to New Research on Sumatriptan

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

Also Known As:

Imigran; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; GR-43175; GSK Brand of Sumatriptan; Glaxo Wellcome Brand of Sumatriptan; Sumatriptan Succinate; GR 43175; GR43175; Succinate, Sumatriptan; Sumatriptan GSK Brand; 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-

Networked: 1204 relevant articles (314 outcomes, 323 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Experts

1.	Goadsby, P J: 9 articles (09/2005 - 01/2000)
2.	Moore, R Andrew: 7 articles (01/2012 - 04/2006)
3.	Derry, Sheena: 7 articles (01/2012 - 04/2006)
4.	Lipton, R B: 7 articles (09/2005 - 02/2001)
5.	Ferrari, M D: 7 articles (09/2005 - 01/2000)
6.	Diener, H C: 6 articles (10/2008 - 01/2001)
7.	Durham, Paul L: 5 articles (01/2012 - 04/2002)
8.	Cady, Roger K: 5 articles (11/2011 - 01/2007)
9.	Tfelt-Hansen, Peer: 4 articles (01/2013 - 12/2006)
10.	Martelletti, Paolo: 4 articles (11/2012 - 09/2008)

Related Diseases

1.	Migraine Disorders (Migraine) 01/01/2003 - "The goal of this study was to determine whether migraine management is improved by providing 3 formulations of sumatriptan succinate to patients, together with education to assist them in selecting the most appropriate formulation for specific attacks. " 05/01/2007 - "The 5-HT(1B/1D) receptor agonist sumatriptan is highly effective in the treatment of migraine. " 04/22/1999 - "Sumatriptan is a highly effective treatment for migraine in adults but its efficacy in children has not been determined. " 02/01/1997 - "Sumatriptan has been shown to be most effective in migraine attacks, but with transient, slight side effects and high rebound attack rates. " 09/01/1996 - "Sumatriptan, notably after subcutaneous administration, is highly effective in the acute treatment of migraine in the majority of patients. " Order ALL the reference details at left...
2.	Headache (Headaches) 04/01/1993 - "In addition, they examine the initial efficacy of treatment and the mechanism of recurrence of headache within 24 hours, which is the most important drawback of sumatriptan in clinical practice, next to its possible cardiac side effects." 01/01/2005 - "A single dose of sumatriptan 10 mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. " 07/01/1994 - "In both studies, headache severity had significantly improved at 120 min after doses of 10-40 mg sumatriptan compared to placebo (P < 0.05) and the greatest efficacy rates were obtained with 20 mg sumatriptan. " 04/01/2008 - "We describe an adolescent with acute posttraumatic headache that did not respond to several initial medications but had rapid and sustained improvement in headache and associated migrainous features with subcutaneous sumatriptan." 04/01/2005 - "For the first attack, significantly more patients receiving sumatriptan than placebo reported headache relief for attacks occurring inside (67% vs. 33%, p=0.007) and outside (79% vs. 31%, p<0.001) the menstrual period. " Order ALL the reference details at left...
3.	Pain (Aches) 09/01/1996 - "Sumatriptan failed to produce a significant reduction in sensory and total pain scores at 60 minutes following treatment, however the result was statistically significant for the affective pain score (P < .05). " 08/01/2007 - "Clinical trials indicate that sumatriptan FDT/RRT is rapidly effective in terms of freedom from pain and return to normal activities, both with early and late treatment. " 04/01/2005 - "Sumatriptan was effective in relieving pain to a certain degree, but the frequency of the occurrence of pain gradually increased. " 12/01/1998 - "Measuring the effectiveness of earlier pain relief with sumatriptan, the incremental cost-effective ratios for direct and total cost were 132 and 53 BF per hour of relieved pain, respectively. " 06/01/2006 - "However, TMB/DPH was well-tolerated, efficacious, and relieved pain comparably to sumatriptan at 24 hours. " Order ALL the reference details at left...
4.	Cluster Headache (Cluster Headaches) 03/01/1998 - "Sumatriptan, an agonist of 5-HT1-like receptors, has proven effective in the treatment of cluster headache attacks. " 11/01/1995 - "Preemptive oral treatment with sumatriptan 100 mg tid for 7 days did not produce a significant reduction in the number or severity of cluster headache attacks occurring during an established cluster headache period. " 01/01/2002 - "Four patients continued to treat all cluster headache attacks with the intranasal sumatriptan formula, two patients had switched to subcutaneous sumatriptan and one patient was in remission since the end of the study. " 09/01/2005 - "We conclude that sumatriptan in doses less than 6 mg can be effective in the acute treatment of cluster headache attacks. " 09/01/2005 - "Subcutaneous (SQ) sumatriptan 6 mg is effective in the treatment of acute cluster headache attacks. " Order ALL the reference details at left...
5.	Nausea 10/07/1995 - "LAS+MTC was significantly more effective in the treatment of nausea than sumatriptan (p < 0.0001) and was better tolerated (adverse events in 18% and 28%, respectively, p < 0.05). " 02/01/2012 - "Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea." 10/01/2006 - "The most commonly reported adverse events were nausea (sumatriptan, 6% and 4%; control, 2% and 2%) and injection-site reaction (ie, burning or stinging at the injection site) (sumatriptan, 5 % and 5%; control, 2% and 1%). " 11/01/2002 - "Sumatriptan modifies gastric size, with a reduction in the transverse section and an increase of the sagittal axis of the proximal stomach and improves the nausea induced by gastric distension in dyspeptic patients." 11/01/2002 - "Among the symptoms evaluated, only nausea was significantly reduced by sumatriptan (P < 0.01). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tablets
2.	Ergotamine (Ergotamine Tartrate)
3.	Serotonin (5 Hydroxytryptamine)
4.	Caffeine (No Doz)
5.	rizatriptan (Maxalt)
6.	Naproxen (Naprosyn)
7.	Tryptamines (Triptans)
8.	zolmitriptan (Zomig)
9.	almotriptan (Axert)
10.	Aspirin (Acetylsalicylic Acid)

Related Therapies and Procedures

1.	Subcutaneous Injections
2.	Oral Administration
3.	Aftercare (After-Treatment)
4.	Intranasal Administration
5.	Emergency Treatment

blog comments powered by Disqus

TREATMENT OPTIONS
for Migraine Disorders,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1291 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>